@article{JTD19733,
author = {Myung-Ju Ahn},
title = {Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {3},
year = {2018},
keywords = {},
abstract = {Stage III non-small cell lung cancer (NSCLC) accounts for one-third of NSCLC patients. Stage IIIA is considered resectable, but most of stage IIIA/B patients are unresectable, leading to chemoradiotherapy being standard of care. The median overall survival remains poor with less than 15% of 5-year overall survival after chemoradiotherapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/19733}
}